MC230715 Pilot Study of the Mechanistic Feedback From CNS Tumors With Latent Residual Disease to Guide Individualized Therapies
This early trial tests a combination of different medications, plant compounds, and a personalized vaccine to treat adults with a specific type of brain tumor called a glioma that has been treated before. The goal is to see if this unique approach is safe and helps stop any remaining cancer cells from growing.
You may be able to join if you are 18 or older, have a glioma brain tumor that was previously treated, and can still do most daily activities on your own. Your tumor also needs to have specific genetic features, and you must not be pregnant or breastfeeding.
Participants will receive a mix of targeted medications, plant-based supplements, chemotherapy, and a personalized vaccine made from their own tumor tissue. You will also have regular health monitoring, imaging scans, and tissue or fluid tests to see how your body responds.
This study is currently recruiting patients and takes place in Rochester, Minnesota, United States.
- 1Tests a combination of medications and a personalized tumor vaccine for brain tumors.
- 2Designed for adults with previously treated glioma who are in good general shape.
- 3Involves close health monitoring, scans, and regular study treatments.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.